WO2000042045A3 - Functionalized heterocycles as chemokine receptor modulators - Google Patents

Functionalized heterocycles as chemokine receptor modulators Download PDF

Info

Publication number
WO2000042045A3
WO2000042045A3 PCT/US1999/030434 US9930434W WO0042045A3 WO 2000042045 A3 WO2000042045 A3 WO 2000042045A3 US 9930434 W US9930434 W US 9930434W WO 0042045 A3 WO0042045 A3 WO 0042045A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
receptor modulators
useful
functionalized heterocycles
modulators
Prior art date
Application number
PCT/US1999/030434
Other languages
French (fr)
Other versions
WO2000042045A2 (en
Inventor
Geraldine C Harriman
Christine Nylund Kolz
Jay R Luly
Bruce David Roth
Yuntao Song
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Geraldine C Harriman
Christine Nylund Kolz
Jay R Luly
Bruce David Roth
Yuntao Song
Bharat Kalidas Trivedi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL99349348A priority Critical patent/PL349348A1/en
Priority to JP2000593612A priority patent/JP2002534526A/en
Priority to KR1020017008905A priority patent/KR20010086166A/en
Priority to MXPA01007033A priority patent/MXPA01007033A/en
Priority to AU19409/00A priority patent/AU1940900A/en
Priority to EP99963110A priority patent/EP1144415A2/en
Priority to HU0202932A priority patent/HUP0202932A3/en
Priority to APAP/P/2001/002228A priority patent/AP2001002228A0/en
Application filed by Warner Lambert Co, Geraldine C Harriman, Christine Nylund Kolz, Jay R Luly, Bruce David Roth, Yuntao Song, Bharat Kalidas Trivedi filed Critical Warner Lambert Co
Priority to CA002372197A priority patent/CA2372197A1/en
Priority to SK997-2001A priority patent/SK9972001A3/en
Priority to BR9916905-3A priority patent/BR9916905A/en
Priority to IL14428999A priority patent/IL144289A0/en
Priority to EA200100774A priority patent/EA200100774A1/en
Publication of WO2000042045A2 publication Critical patent/WO2000042045A2/en
Publication of WO2000042045A3 publication Critical patent/WO2000042045A3/en
Priority to NO20013456A priority patent/NO20013456L/en
Priority to HK02106357.2A priority patent/HK1044539A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is a novel series of functionalized heterocycles as chemokine receptor modulators of Formula (I) useful as modulators of chemokine receptor activity. The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the prepartion of the final products, pharmaceutical compositions containing the final products are also taught.
PCT/US1999/030434 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators WO2000042045A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA002372197A CA2372197A1 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators
JP2000593612A JP2002534526A (en) 1999-01-13 1999-12-20 Functionalized heterocycles as modulators of chemokine receptors
SK997-2001A SK9972001A3 (en) 1999-01-13 1999-12-20 Quinolizine derivative, pharmaceutical composition containing same and use thereof
AU19409/00A AU1940900A (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators
EP99963110A EP1144415A2 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators
HU0202932A HUP0202932A3 (en) 1999-01-13 1999-12-20 Heterocyclic compounds and pharmaceutical compositions can be used as chemokine receptor modulators
APAP/P/2001/002228A AP2001002228A0 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators.
PL99349348A PL349348A1 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators
KR1020017008905A KR20010086166A (en) 1999-01-13 1999-12-20 Functionalized Heterocycles as Chemokine Receptor Modulators
MXPA01007033A MXPA01007033A (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators.
BR9916905-3A BR9916905A (en) 1999-01-13 1999-12-20 Compound, pharmaceutical composition, methods to modulate the activity of a chemokine receptor, to prevent HIV infection, to treat HIV infection, to delay the onset of AIDS, or to treat AIDS and to treat an inflammatory disease, and, combination
IL14428999A IL144289A0 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators
EA200100774A EA200100774A1 (en) 1999-01-13 1999-12-20 HYDRONIC
NO20013456A NO20013456L (en) 1999-01-13 2001-07-12 Functionalized heterocycles as chemokine receptor modulators
HK02106357.2A HK1044539A1 (en) 1999-01-13 2002-08-28 Functionalized heterocycles as chemokine receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11565499P 1999-01-13 1999-01-13
US60/115,654 1999-01-13

Publications (2)

Publication Number Publication Date
WO2000042045A2 WO2000042045A2 (en) 2000-07-20
WO2000042045A3 true WO2000042045A3 (en) 2000-11-09

Family

ID=22362668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030434 WO2000042045A2 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators

Country Status (20)

Country Link
EP (1) EP1144415A2 (en)
JP (1) JP2002534526A (en)
KR (1) KR20010086166A (en)
CN (1) CN1344270A (en)
AP (1) AP2001002228A0 (en)
AU (1) AU1940900A (en)
BR (1) BR9916905A (en)
CA (1) CA2372197A1 (en)
CZ (1) CZ20012502A3 (en)
EA (1) EA200100774A1 (en)
HK (1) HK1044539A1 (en)
HU (1) HUP0202932A3 (en)
IL (1) IL144289A0 (en)
MX (1) MXPA01007033A (en)
NO (1) NO20013456L (en)
OA (1) OA11820A (en)
PL (1) PL349348A1 (en)
SK (1) SK9972001A3 (en)
WO (1) WO2000042045A2 (en)
ZA (1) ZA200106592B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072549A1 (en) * 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DK1379239T3 (en) 2001-03-29 2008-01-07 Lilly Co Eli N (2-aryl-ethyl) -benzylamines as antagonists of the HT6 receptor
WO2003035650A1 (en) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
MXPA05009771A (en) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient.
WO2004092169A1 (en) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (en) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP5251127B2 (en) 2005-10-28 2013-07-31 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
PT1961744E (en) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Basic group-containing compound and use thereof
CN101460458A (en) 2006-02-15 2009-06-17 阿勒根公司 Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
BRPI0707873A2 (en) * 2006-02-15 2011-05-10 Allergan Inc amide, ester, thioamide and thiol compounds Indole-3-carboxylic acid ester carrying aryl or heteroaryl groups having biologically sphingosine-1-phosphate receptor antagonist activity (s1p)
BRPI0708731A2 (en) 2006-03-10 2011-06-07 Ono Pharmaceutical Co nitrogenous heterocyclic derivative, and pharmaceutical agent comprising the derivative as an active ingredient
WO2007132846A1 (en) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US8329689B2 (en) 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101668741A (en) 2007-01-11 2010-03-10 阿勒根公司 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CN102958927A (en) 2010-05-12 2013-03-06 Abbvie公司 Indazole inhibitors of kinase
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JO3459B1 (en) 2012-09-09 2020-07-05 H Lundbeck As Pharmaceutical compositions for treating alzheimer's disease
CN104193669B (en) * 2014-08-01 2016-12-07 大连理工大学 One class Abiduoer analog or its salt, its preparation method and application
WO2016112088A1 (en) * 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
CN110256324A (en) * 2019-06-13 2019-09-20 苏州莱安医药化学技术有限公司 A kind of preparation method of 2- methyl -5-OHi
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518258A (en) * 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3549641A (en) * 1966-06-28 1970-12-22 Warner Lambert Pharmaceutical Pyrano pyridines and process for their production
US3565903A (en) * 1967-11-24 1971-02-23 Warner Lambert Pharmaceutical Pyrano(2,3-b)quinolines and process for their production
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
EP0820998A2 (en) * 1996-07-26 1998-01-28 PLIVA, farmaceutska, kemijska, prehrambena i kozmeticka industrija dionicko drustvo Novel coumarin quinolone carboxylic acids and processes for the preparation thereof
WO1998038167A1 (en) * 1997-02-26 1998-09-03 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
WO1999038514A1 (en) * 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549641A (en) * 1966-06-28 1970-12-22 Warner Lambert Pharmaceutical Pyrano pyridines and process for their production
US3518258A (en) * 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3565903A (en) * 1967-11-24 1971-02-23 Warner Lambert Pharmaceutical Pyrano(2,3-b)quinolines and process for their production
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
EP0820998A2 (en) * 1996-07-26 1998-01-28 PLIVA, farmaceutska, kemijska, prehrambena i kozmeticka industrija dionicko drustvo Novel coumarin quinolone carboxylic acids and processes for the preparation thereof
WO1998038167A1 (en) * 1997-02-26 1998-09-03 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
WO1999038514A1 (en) * 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. VON STRANDTMANN ET AL.: "Reaction of Phenolic Mannich Bases with Enamines. General Synthesis of Pyran-Containing Fused Ring Systems.", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 7, 1970, HETEROCORPORATION. PROVO., US, pages 1311 - 1319, XP002143638, ISSN: 0022-152X *

Also Published As

Publication number Publication date
OA11820A (en) 2005-08-17
KR20010086166A (en) 2001-09-08
JP2002534526A (en) 2002-10-15
AU1940900A (en) 2000-08-01
HK1044539A1 (en) 2002-10-25
NO20013456L (en) 2001-09-12
AP2001002228A0 (en) 2001-09-30
NO20013456D0 (en) 2001-07-12
WO2000042045A2 (en) 2000-07-20
EP1144415A2 (en) 2001-10-17
CZ20012502A3 (en) 2002-03-13
MXPA01007033A (en) 2003-07-21
CN1344270A (en) 2002-04-10
EA200100774A1 (en) 2002-02-28
IL144289A0 (en) 2002-05-23
SK9972001A3 (en) 2002-03-05
PL349348A1 (en) 2002-07-15
HUP0202932A3 (en) 2003-07-28
CA2372197A1 (en) 2000-07-20
BR9916905A (en) 2002-01-29
HUP0202932A2 (en) 2002-12-28
ZA200106592B (en) 2002-08-12

Similar Documents

Publication Publication Date Title
WO2000042045A3 (en) Functionalized heterocycles as chemokine receptor modulators
WO2002100844A3 (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
AU6461600A (en) Substituted piperidine compounds useful as modulators of chemokine receptor activity
WO2004071426A3 (en) Compounds for the treatment of viral infection
WO2000059497A8 (en) Pyrrolidine modulators of chemokine receptor activity
MXPA04002982A (en) Pyrrolidinone derivatives.
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
MY125749A (en) Aralkyl and aralkylidene heterocyclic lactams and imides
CA2243504A1 (en) New 19-nor-pregnene derivatives
WO2004042351A3 (en) Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
ZA200110540B (en) Novel diphenyl-piperidine derivate.
WO2004041777A3 (en) Heteroarylpiperidine modulators of chemokine receptor activity
MY124146A (en) Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
AU2001232556A1 (en) Pyrimidine compounds and their use as modulators of chemokine receptor activity
FR2715402B1 (en) New phenylimidazolines optionally substituted, their process and preparation intermediates, their use as medicaments and the pharmaceutical compositions containing them.
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
AU5692500A (en) Piperazine derivatives as modulators of chemokine receptor activity
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU4568400A (en) Sphingomyelinase inhibitor
WO2003049695A3 (en) Compounds to treat hiv infection and aids

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816475.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PV2001-2502

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007033

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2372197

Country of ref document: CA

Ref document number: 2372197

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144289

Country of ref document: IL

Ref document number: 9972001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 593612

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017008905

Country of ref document: KR

Ref document number: A 2001 00806

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1999963110

Country of ref document: EP

Ref document number: IN/PCT/2001/1088/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 513435

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/06592

Country of ref document: ZA

Ref document number: 200106592

Country of ref document: ZA

Ref document number: 19409/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200100774

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020017008905

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999963110

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889315

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-2502

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999963110

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-2502

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017008905

Country of ref document: KR